What side effects are associated with this type of intervention?

Common cancer treatments, including chemotherapy, targeted therapy, and immunotherapy, have a range of side effects. Chemotherapy can cause nausea, vomiting, hair loss, fatigue, and increased infection risk due to bone marrow suppression. Targeted therapies, such as tyrosine kinase inhibitors and mTOR inhibitors, may lead to skin rashes, diarrhea, liver toxicity, and hypertension. Immunotherapy, including checkpoint inhibitors like pembrolizumab, can result in immune-related adverse effects such as colitis, pneumonitis, hepatitis, and endocrinopathies. The severity and frequency of these side effects depend on the specific drug and individual patient factors.

What prior FDA approvals exist?

The FDA has approved several targeted therapies and immunotherapies for cancer treatment. For instance, dabrafenib and trametinib are approved for BRAF V600-mutant melanoma, targeting the BRAF protein and MEK pathway, respectively. Pembrolizumab and nivolumab, both PD-1 inhibitors, are approved for various cancers, including melanoma and head and neck cancer, enhancing the immune system's ability to fight cancer. Additionally, eribulin, a microtubule dynamics inhibitor, is approved for advanced liposarcoma and leiomyosarcoma. These approvals highlight the FDA's focus on therapies that target specific molecular pathways or enhance immune response to combat cancer.

What other types of research exist?

Promising novel alternatives to RP-6306 for cancer treatment in 2024 include: 1) Selpercatinib and pralsetinib, which are selective RET inhibitors for RET-mutated tumors. 2) Anti-PD-1 therapies like nivolumab, potentially combined with anti-CTLA-4 therapy, for various cancers including LCNEC. 3) PARP inhibitors such as olaparib and niraparib, particularly for cancers with BRCA1/2 mutations or other homologous recombination repair deficiencies. 4) Bevacizumab, an angiogenesis inhibitor, used in combination with platinum-based chemotherapy for ovarian cancer. These therapies target specific molecular pathways and have shown promising results in clinical trials.

← Back to Search

Other

RP-6306 Combination Therapy for Cancer

Phase 2

Recruiting

Research Sponsored by Canadian Cancer Trials Group

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing RP-6306, a new drug, to see if it can help treat cancer when used with standard treatments. It focuses on patients with specific biomarkers to see if they respond better. The drug works by blocking a protein that helps cancer cells grow.

Who is the study for?

Adults with advanced cancers like endometrial, NSCLC, ovarian carcinosarcoma, TNBC, PDAC, colorectal cancer or HER-2+ gastroesophageal cancer. They must have tried some treatments already (like platinum-based chemotherapy), be in good physical condition and expected to live at least 3 months. Specific genetic markers are required for some cohorts. Pregnant women and those with certain health conditions or previous hypersensitivity to study drugs can't join.

What is being tested?

The trial is testing RP-6306's safety and effectiveness against various advanced cancers when combined with standard treatments such as Gemcitabine or FOLFIRI Protocol. It also examines if patients' biomarkers affect their response to the treatment compared to usual cancer care approaches.

What are the potential side effects?

Potential side effects of RP-6306 and other drugs used in this trial may include reactions related to drug infusion, impact on blood cells leading to increased infection risk, fatigue, digestive issues due to oral medication absorption problems, and possibly organ inflammation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Active Control

Group I: RP-6306 + TrastuzumabActive Control2 Interventions

Group II: RP-6306 + GemcitabineActive Control2 Interventions

Group III: RP-6306 + FOLFIRIActive Control2 Interventions

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Cancer treatments work through various mechanisms to target and destroy cancer cells. Chemotherapy uses drugs to kill rapidly dividing cells, affecting both cancerous and some healthy cells. Targeted therapies, like those being studied in trials such as RP-6306, focus on specific molecules or pathways crucial for cancer cell growth and survival, thereby minimizing damage to normal cells. Immunotherapy boosts the body's immune system to recognize and attack cancer cells. Radiation therapy uses high-energy particles to damage the DNA of cancer cells, leading to cell death. Understanding these mechanisms helps patients and doctors choose the most effective treatment plan, manage side effects, and improve overall outcomes.

Emerging treatments in lung cancer - targeting the RLIP76 molecular transporter.Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology.Overcoming therapeutic resistance in malignant gliomas: current practices and future directions.